Loading clinical trials...
Loading clinical trials...
This first-in-human study is designed to establish the safety and tolerability of ATR-101 in patients with advanced adrenocortical carcinoma whose tumor has progressed on standard therapy. Information...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Millendo Therapeutics, Inc.
NCT07244458 · Dietary Change, Obesity & Overweight, and more
NCT03050268 · Acute Leukemia, Adenomatous Polyposis, and more
NCT07292883 · Tobacco Use Disorder, Addiction Nicotine
NCT05475925 · LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous Gamma-Delta T-Cell Lymphoma, and more
NCT07054099 · Varicella (Chickenpox), Chickenpox Vaccine
Moffitt Cancer Center
Tampa, Florida
National Institutes of Health/National Cancer Institute
Bethesda, Maryland
University of Michigan Cancer Center
Ann Arbor, Michigan
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions